Literature DB >> 1987733

Radiation therapy of pituitary tumors: results in 95 cases.

L M Tran1, L Blount, D Horton, A Sadeghi, R G Parker.   

Abstract

Between 1967 and 1985 95 patients with pituitary adenoma received radiation therapy at the University of California, Los Angeles (UCLA), and the West Los Angeles Veterans' Administration (VA) Medical Center. Seventy of these patients received radiation therapy immediately as adjuvant therapy following incomplete resection, and 25 were irradiated as primary treatment or after surgical failure. The majority of cases (87%) presented clinically with macroadenomas. Two-thirds of the patients were treated with parallel opposed lateral portals to a midline total dose of 50 Gy. The mean follow-up was 7 years (range: 30-250 months). In our series, there is a difference in response by disease subtype. The control rates were 83% (30 of 36) for nonfunctioning adenoma, 60% (nine of 15) for growth-hormone secreting adenoma, 44% (16 of 36) for prolactin secreting adenoma, three of five for Nelson's syndrome, and three of three for Cushing's disease. There was a tendency for a better response rate with a total dose of greater than or equal to 50 Gy for prolactinoma. None of the patients were known to develop brain necrosis or radiation-induced sarcoma. An analysis of these results and a review of the literature is presented here.

Entities:  

Mesh:

Year:  1991        PMID: 1987733     DOI: 10.1097/00000421-199102000-00005

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  12 in total

1.  [Fractionated stereotactic-guided radiotherapy in the treatment of pituitary adenomas].

Authors:  Rosa M Cañón Rodríguez; David Ortiz de Urbina; Juan Carlos Viera; César Beltrán; Fernando Puebla; M Isabel García Berrocal; Ana Mañas; Carmen Peraza; Felipe A Calvo
Journal:  Clin Transl Oncol       Date:  2005-11       Impact factor: 3.405

2.  Outcomes of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for refractory Cushing's disease.

Authors:  Alexander D Sherry; Mohamed H Khattab; Mark C Xu; Patrick Kelly; Joshua L Anderson; Guozhen Luo; Andrea L Utz; Lola B Chambless; Anthony J Cmelak; Albert Attia
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

3.  Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.

Authors:  D Kojo Hamilton; Mary Lee Vance; Paul T Boulos; Edward R Laws
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

4.  Evaluation of modern pathologic nomenclature, tumor imaging and treatment of pituitary adenomas in a recent surgical series.

Authors:  A Y Cheung; T Sligh; S Bauserman; G Schultz
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

Review 5.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

6.  Percutaneous transluminal angioplasty in a patient with internal carotid artery stenosis following gamma knife radiosurgery for recurrent pituitary adenoma.

Authors:  Hidemichi Ito; Hidetaka Onodera; Taigen Sase; Masashi Uchida; Hiroyuki Morishima; Kotaro Oshio; Takashi Shuto; Yuichiro Tanaka
Journal:  Surg Neurol Int       Date:  2015-05-28

Review 7.  Diagnosis and management of pituitary tumours.

Authors:  A Levy; S L Lightman
Journal:  BMJ       Date:  1994-04-23

8.  Stereotactic Radiosurgery with the CyberKnife for Pituitary Adenomas.

Authors:  Chul Bum Cho; Hae Kwan Park; Won Il Joo; Chung Kee Chough; Kyung Jin Lee; Hyoung Kyun Rha
Journal:  J Korean Neurosurg Soc       Date:  2009-03-31

Review 9.  Cushing's disease: radiation therapy.

Authors:  Mary Lee Vance
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 10.  Radiation therapy for Cushing's disease: a review.

Authors:  Ashraf S Mahmoud-Ahmed; John H Suh
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.